Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
REGN Stock Forecast 2026-2027
$664.45
Current Price
$68.79B
Market Cap
Buy 21
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to REGN Price Targets
+50.5%
To High Target of $1,000.00
+26.0%
To Median Target of $837.50
-3.5%
To Low Target of $641.00
REGN Price Momentum
-0.5%
1 Week Change
+8.1%
1 Month Change
+21.3%
1 Year Change
-13.9%
Year-to-Date Change
-19.1%
From 52W High of $821.11
+22.8%
From 52W Low of $541.00
📊 TOP ANALYST CALLS
Did REGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Regeneron is one of their latest high-conviction picks.
Latest REGN Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, REGN has a bullish consensus with a median price target of $837.50 (ranging from $641.00 to $1,000.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $664.45, the median forecast implies a 26.0% upside. This outlook is supported by 21 Buy, 8 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
REGN Analyst Ratings
21
Buy
8
Hold
0
Sell
REGN Price Target Range
Low
$641.00
Average
$837.50
High
$1,000.00
Current: $664.45
Latest REGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for REGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 9, 2026 | Piper Sandler | Biren Amin | Overweight | Maintains | $854.00 |
| Jul 8, 2026 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $730.00 |
| Jul 7, 2026 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $696.00 |
| Jul 7, 2026 | Truist Securities | Gregory Renza | Buy | Maintains | $769.00 |
| Jul 7, 2026 | Benchmark | Robert Wasserman | Buy | Upgrade | $185.00 |
| Jul 6, 2026 | HSBC | Rajesh Kumar | Buy | Maintains | $880.00 |
| Jul 6, 2026 | Cantor Fitzgerald | Carter Gould | Overweight | Maintains | $750.00 |
| May 19, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 18, 2026 | BMO Capital | Outperform | Maintains | $N/A | |
| May 18, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| May 18, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| May 18, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 18, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 18, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| May 18, 2026 | Citigroup | Neutral | Downgrade | $N/A | |
| May 18, 2026 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| May 1, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Apr 30, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Apr 30, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 30, 2026 | Truist Securities | Buy | Maintains | $N/A |
Regeneron Pharmaceuticals, Inc. (REGN) Competitors
The following stocks are similar to Regeneron based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Regeneron Pharmaceuticals, Inc. (REGN) Financial Data
Regeneron Pharmaceuticals, Inc. has a market capitalization of $68.79B with a P/E ratio of 16.2x. The company generates $14.92B in trailing twelve-month revenue with a 29.6% profit margin.
Revenue growth is +19.0% quarter-over-quarter, while maintaining an operating margin of +20.7% and return on equity of +14.5%.
Valuation Metrics
Market Cap
$68.79B
Enterprise Value
$61.41B
P/E Ratio
16.2x
PEG Ratio
-2.1x
Price/Sales
4.6x
Growth & Margins
Revenue Growth (YoY)
+19.0%
Gross Margin
+81.4%
Operating Margin
+20.7%
Net Margin
+29.6%
EPS Growth
-10.1%
Financial Health
Cash/Price Ratio
+12.9%
Current Ratio
3.6x
Debt/Equity
8.6x
ROE
+14.5%
ROA
+6.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Regeneron Pharmaceuticals, Inc. (REGN) Business Model
About Regeneron Pharmaceuticals, Inc.
What They Do
Biotechnology company developing medicines for serious diseases.
Business Model
The company generates revenue by discovering, developing, and commercializing innovative medicines across various therapeutic areas, including eye care, immunology, oncology, and more. Its revenue streams primarily come from the sale of prescription medicines, which are used by patients and healthcare providers in specialized care settings.
Additional Information
Regeneron has a diverse portfolio of treatments, including Eylea for eye disorders and Dupixent for allergic conditions. The company also engages in collaboration with partners for advanced research programs, focusing on antibody-based therapies, and is headquartered in Tarrytown, New York.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15,343
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Country
United States
IPO Year
1991
Website
www.regeneron.comRegeneron Pharmaceuticals, Inc. (REGN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jul 07, 2026
By Zacks Equity Research
Tale of the Tape
Here's Why Regeneron (REGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jul 07, 2026
By Zacks Equity Research
Tale of the Tape
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Jul 06, 2026
By Ahan Chakraborty
Analyst Blog
Latest News
Quick Summary
Delivery Hero and Canal+ positively contributed to the quarter, while IDP Education was a detractor. Positions in Delivery Hero and Menicon were exited as they neared fair value.
Why It Matters
Delivery Hero's exit signals a strategic shift, potentially affecting future growth. Canal+'s positive contribution may boost confidence, while IDP Education's poor performance raises concerns.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Booking Holdings, Alphabet, and six other companies have lagged behind their sectors despite better earnings expectations, indicating potential upside in the upcoming second-quarter earnings season.
Why It Matters
Underperformance amid rising earnings expectations signals potential stock price recovery for these companies, offering investors opportunities for gains in the upcoming earnings season.
Source: Barrons
Market Sentiment:
Positive
Quick Summary
In Q2 2026, Baird Chautauqua International Growth Fund returned +10.39%, underperforming the MSCI ACWI ex-U.S. Index (+14.49%). Key detractors included Alibaba and Lululemon. The Global Growth Fund returned +12.18%, also underperforming the MSCI ACWI Index (+14.93%).
Why It Matters
The underperformance of the Baird Chautauqua funds against their benchmarks signals potential concerns about their investment strategy and stock selection, influencing investor confidence and future allocations.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Regeneron (REGN) has a strong earnings surprise history and appears well-positioned for a potential earnings beat in its upcoming quarterly report.
Why It Matters
Regeneron's strong earnings surprise history and favorable indicators suggest potential for positive earnings surprises, which can boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a tool for informed stock selection.
Why It Matters
The Zacks Style Scores provide a streamlined method for identifying high-potential stocks, aiding investors in making informed decisions aligned with their strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Jim Cramer on CNBC indicated a bullish outlook for the biotech sector, suggesting a potential wave of mergers and acquisitions due to a more favorable regulatory environment.
Why It Matters
Cramer's bullish call on biotech signals potential M&A activity, which can drive stock prices up and reshape the sector's landscape, presenting new investment opportunities.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Frequently Asked Questions About REGN Stock
What is Regeneron Pharmaceuticals, Inc.'s (REGN) stock forecast for 2027?
Based on our analysis of 11 Wall Street analysts, Regeneron Pharmaceuticals, Inc. (REGN) has a median price target of $837.50. The highest price target is $1,000.00 and the lowest is $641.00.
Is REGN stock a good investment in 2027?
According to current analyst ratings, REGN has 21 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $664.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for REGN stock?
Wall Street analysts predict REGN stock could reach $837.50 in the next 12 months. This represents a 26.0% increase from the current price of $664.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Regeneron Pharmaceuticals, Inc.'s business model?
The company generates revenue by discovering, developing, and commercializing innovative medicines across various therapeutic areas, including eye care, immunology, oncology, and more. Its revenue streams primarily come from the sale of prescription medicines, which are used by patients and healthcare providers in specialized care settings.
What is the highest forecasted price for REGN Regeneron Pharmaceuticals, Inc.?
The highest price target for REGN is $1,000.00 from at , which represents a 50.5% increase from the current price of $664.45.
What is the lowest forecasted price for REGN Regeneron Pharmaceuticals, Inc.?
The lowest price target for REGN is $641.00 from at , which represents a -3.5% decrease from the current price of $664.45.
What is the overall REGN consensus from analysts for Regeneron Pharmaceuticals, Inc.?
The overall analyst consensus for REGN is bullish. Out of 11 Wall Street analysts, 21 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $837.50.
How accurate are REGN stock price projections?
Stock price projections, including those for Regeneron Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:36 PM UTC